Two of the most-discussed peptides in current metabolic research are tirzepatide and retatrutide. They are often mentioned together because both are incretin-based peptides, but they differ in a fundamental way. This guide compares what the published scientific literature has examined about each. It is written for researchers and is not medical guidance.
Research-use note: Both compounds discussed here are supplied strictly for laboratory research. They are not supplements and not for human or animal consumption. Nothing below describes or endorses human use.
Evidence at a glance
Human trials at different stagesBoth have real human trial data, but at genuinely different stages. Tirzepatide has Phase 3 evidence and approval. Retatrutide has Phase 2 only.
Why researchers are interested
The difference is how many receptors each one works on. Tirzepatide is dual, covering GIP and GLP-1. Retatrutide adds glucagon, which raises energy expenditure on top of appetite reduction, and that third arm is the accepted explanation for its larger Phase 2 weight results.
What the research found
- Tirzepatide beat semaglutideGreater HbA1c reduction in a direct Phase 3 head to head (SURPASS-2)
- Tirzepatide, weight reductionSignificant weight loss across the SURMOUNT programme
- Retatrutide, larger weight lossRoughly 24 percent mean body weight reduction at the top dose at 48 weeks (Jastreboff, NEJM 2023)
- Retatrutide, blood sugar controlHbA1c reductions in type 2 diabetes (Rosenstock, Lancet 2023)
Reported in the literature
- Both report dose related gastrointestinal effects, mainly nausea, vomiting and diarrhoea, as the dominant finding.
- Tirzepatide carries a boxed warning for rodent thyroid C-cell tumours, plus pancreatitis and gallbladder warnings.
- Retatrutide trials observed increases in heart rate.
- Retatrutide has no published Phase 3 or long term outcome data, so the two cannot be compared on long term safety.
Findings are summarised from the sources listed under References on this page, and from approved product labelling where a compound has one. These are outcomes observed in published studies, not effects claimed for any person, and nothing here is a recommendation for human use.
The core difference: dual vs. triple agonist
The defining distinction is how many receptors each peptide engages:
- Tirzepatide is a dual agonist: it activates the GIP and GLP-1 receptors.
- Retatrutide is a triple agonist: it activates GIP, GLP-1, and additionally the glucagon receptor.
That added glucagon-receptor activity is the single structural difference researchers point to when distinguishing retatrutide from tirzepatide in the literature.
Side-by-side comparison
| Property | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor targets | GIP + GLP-1 (dual) | GIP + GLP-1 + glucagon (triple) |
| Developmental code | LY3298176 | LY3437943 |
| CAS number | 2023788-19-2 | 2381089-83-2 |
| Molecular formula | C225H348N48O68 | C221H342N46O68 |
| Regulatory status | Approved as a prescription medicine (elsewhere) | Investigational drug candidate |
| Most-cited research | SURPASS / SURMOUNT trials | Phase 2 obesity & type 2 diabetes trials |
What the research has examined
Tirzepatide has the larger published clinical record, including the SURPASS program in type 2 diabetes (e.g. Frías et al., NEJM, 2021) and SURMOUNT in obesity (Lancet, 2023). Retatrutide is newer, with phase 2 data in obesity (Jastreboff et al., NEJM, 2023) and type 2 diabetes (Rosenstock et al., Lancet, 2023). In both cases these are studies of drug candidates, the findings belong to the research record and do not represent approved or validated uses of the research compounds sold here.
Which is relevant for which research?
For researchers studying dual incretin (GIP/GLP-1) pathways, tirzepatide is the reference compound with the deepest literature. For those investigating the addition of glucagon-receptor activity to incretin signaling, retatrutide is the compound of interest. Many research programs reference both to contrast dual- versus triple-agonism. Read the deeper background in our tirzepatide research guide and retatrutide research guide.
For research use only
All products and information referenced here are intended strictly for laboratory and scientific research use only. They are not for human or animal consumption and are not drugs, foods, supplements, or medical devices. No statement here should be interpreted as medical advice.
Shop these research peptides
- Tirzepatide 20mg, GIP/GLP-1 dual agonist, verified specifications
- Retatrutide (GLP-3), GIP/GLP-1/glucagon triple agonist, verified specifications
- Bacteriostatic Water 30ml, reconstitution diluent
References
- Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021. PubMed
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. N Engl J Med. 2023. PubMed
- Rosenstock J, et al. Retatrutide for people with type 2 diabetes: a phase 2 trial. Lancet. 2023. PubMed